VBI Vaccines (NASDAQ:VBIV) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Performance

Shares of VBIV stock opened at $0.63 on Thursday. VBI Vaccines has a 52-week low of $0.45 and a 52-week high of $3.53. The firm has a market capitalization of $18.02 million, a P/E ratio of -0.05 and a beta of 1.93. The stock has a 50 day moving average price of $0.61 and a 200 day moving average price of $0.61.

Institutional Investors Weigh In On VBI Vaccines

A number of institutional investors and hedge funds have recently modified their holdings of VBIV. Engineers Gate Manager LP purchased a new position in VBI Vaccines during the 1st quarter worth $26,000. Point72 Hong Kong Ltd purchased a new position in VBI Vaccines during the 2nd quarter worth $29,000. Barclays PLC increased its holdings in VBI Vaccines by 89.9% during the 1st quarter. Barclays PLC now owns 98,337 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 46,566 shares during the period. Voya Investment Management LLC increased its holdings in VBI Vaccines by 29.7% during the 4th quarter. Voya Investment Management LLC now owns 95,428 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 21,824 shares during the period. Finally, BNP Paribas Arbitrage SA increased its holdings in VBI Vaccines by 208.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 47,668 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 32,227 shares during the period. 12.26% of the stock is owned by institutional investors.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.